Adenosine deaminase (ADA)-resistant analog of deoxyadenosine. Exhibits anti-leukemic activity; Inhibits cell growth of lymphoid and myeloid neoplasm (IC50
= 20 - 87 nM). Pro-apoptotic; induces DNA double-strand breaks. Also inhibits ribonuclease reductase (IC50
= 0.11 - 0.28 μ
M). Displays activity in vitro
and in vivo
. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.
Bryson et al.
Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies.
Robak et al.
Recent Pat. Anticancer Drug Discov., 2006;1:23
Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.
Seto et al.
J. Clin. Invest., 1985;75:377
The citations listed below are publications that use Tocris products. Selected citations for Cladribine include:
Showing Results 1 - 1 of 1